Select area to zoom
Created with Highcharts 11.1.0Apr '24Jul '24Oct '24Jan '25200.00140.87

Profile

Edit
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
URL https://www.biogen.com
Investor Relations URL https://investors.biogen.com
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release Apr. 24, 2025 (est.)
Last Earnings Release Feb. 12, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
URL https://www.biogen.com
Investor Relations URL https://investors.biogen.com
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release Apr. 24, 2025 (est.)
Last Earnings Release Feb. 12, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows